New aldose reductase inhibitors as potential agents for the prevention of long-term diabetic complications

The results of recent clinical trials emphasise the importance of an improved glycaemic control in diabetic patients in order to prevent or at least to delay long-term complications. The difficulty in obtaining normalisation of blood glucose values has underlined the importance of the search for new and effective aldose reductase inhibitors (ARIs) to control the consequences of elevated glucose levels, therefore delaying the onset and retarding the progression of diabetic complications such as neuropathy, nephropathy, retinopathy and cataract. Although the physiological role of aldose reductase (ALR2) has not been clearly elucidated yet, it has been shown that this enzyme, the first of the polyol pathway, is responsible for the production of sorbitol from glucose. There are several pieces of evidence which link this process to the occurrence of diabetic complications. Orally active aldose reductase inhibitors can be grouped into two chemical classes: cyclic imide and carboxylic acid derivatives. This revi...

[1]  K. Okamoto,et al.  Highly Selective Aldose Reductase Inhibitors. Part 2. Optimization of the Aryl Part of 3-(Arylmethyl)-2,4,5-trioxoimidazolidine-1-acetic Acids. , 1997 .

[2]  K. Okamoto,et al.  Highly selective aldose reductase inhibitors. 3. Structural diversity of 3-(arylmethyl)-2,4,5-trioxoimidazolidine-1-acetic acids. , 1997, Journal of medicinal chemistry.

[3]  N. Abe,et al.  Effects of a novel potent aldose reductase inhibitor, GP-1447, on aldose reductase activity in vitro and on diabetic neuropathy and cataract formation in rats. , 1997, Japanese journal of pharmacology.

[4]  R. Ramasamy,et al.  Aldose Reductase Inhibition Protects Diabetic and Nondiabetic Rat Hearts from Ischemic Injury , 1997, Diabetes.

[5]  H. G. Vogel.  Drug Discovery and Evaluation: Pharmacological Assays , 1997 .

[6]  F. Quiocho,et al.  Specifically Targeted Modification of Human Aldose Reductase by Physiological Disulfides* , 1996, The Journal of Biological Chemistry.

[7]  J. Jez,et al.  Characterization of the substrate binding site in rat liver 3alpha-hydroxysteroid/dihydrodiol dehydrogenase. The roles of tryptophans in ligand binding and protein fluorescence. , 1996, The Journal of biological chemistry.

[8]  G. Rastelli,et al.  Synthesis, activity, and molecular modeling of a new series of tricyclic pyridazinones as selective aldose reductase inhibitors. , 1996, Journal of medicinal chemistry.

[9]  T. Nakano,et al.  Kinetic and spectroscopic evidence for active site inhibition of human aldose reductase. , 1996, Biochemistry.

[10]  E. Niki,et al.  Synthesis and aldose reductase-inhibitory activity of imidazopyrroloquinoline esters. , 1996, Chemical & pharmaceutical bulletin.

[11]  K. Okamoto,et al.  Highly Selective Aldose Reductase Inhibitors. Part 1. 3‐(Arylalkyl)‐2, 4,5‐trioxoimidazolidine‐1‐acetic Acids. , 1996 .

[12]  M. Schwartz,et al.  Diabetes Complications--Why Is Glucose Potentially Toxic? , 1996, Science.

[13]  K. Okamoto,et al.  Highly selective aldose reductase inhibitors. 1. 3-(Arylalkyl)-2,4,5-trioxoimidazolidine-1-acetic acids. , 1996, Journal of Medicinal Chemistry.

[14]  N. Ansari,et al.  Semi-quantitation of mRNA by polymerase chain reaction. Levels of oxidative defense enzymes and aldose reductase in rat lenses cultured in hyperglycemic or oxidative medium. , 1996, Research communications in molecular pathology and pharmacology.

[15]  C. Lai,et al.  Oxidized aldose reductase: in vivo factor not in vitro artifact. , 1996, Archives of biochemistry and biophysics.

[16]  J. Lehmann,et al.  The structure - Activity relationship between peroxisome proliferator-activated receptor γ agonism and the antihyperglycemic activity of thiazolidinediones , 1996 .

[17]  R. Eaton,et al.  Increased levels of methylglyoxal-metabolizing enzymes in mononuclear and polymorphonuclear cells from insulin-dependent diabetic patients with diabetic complications: aldose reductase, glyoxalase I, and glyoxalase II--a clinical research center study. , 1996, The Journal of clinical endocrinology and metabolism.

[18]  I. Kubo,et al.  Inhibition of aldose reductase by maesanin and related p-benzoquinone derivatives and effects on other enzymes. , 1996, Bioorganic & medicinal chemistry.

[19]  P. Kador,et al.  Identification of an aldose reductase inhibitor site by affinity labeling. , 1995, Bioorganic & medicinal chemistry.

[20]  T. Flynn,et al.  Catalysis of reduction of carbohydrate 2-oxoaldehydes (osones) by mammalian aldose reductase and aldehyde reductase. , 1995, Biochimica et biophysica acta.

[21]  W. Ward,et al.  Kinetic characteristics of ZENECA ZD5522, a potent inhibitor of human and bovine lens aldose reductase. , 1995, Biochemical pharmacology.

[22]  A. Del Corso,et al.  Occurrence of glutathione-modified aldose reductase in oxidatively stressed bovine lens. , 1995, Biochemical and biophysical research communications.

[23]  M. Malamas,et al.  N-Substituted Spirosuccinimide, Spiropyridazine, Spiroazetidine, and Acetic Acid Aldose Reductase Inhibitors Derived from Isoquinoline-1,3- diones. Part 2. , 1994 .

[24]  R. G. Brown,et al.  Vitamin C: an aldose reductase inhibitor that normalizes erythrocyte sorbitol in insulin-dependent diabetes mellitus. , 1994, Journal of the American College of Nutrition.

[25]  L. Diemel,et al.  Aldose reductase inhibitors and their potential for the treatment of diabetic complications. , 1994, Trends in pharmacological sciences.

[26]  M. Malamas,et al.  Novel spirosuccinimide aldose reductase inhibitors derived from isoquinoline-1,3-diones: 2-[(4-bromo-2-fluorophenyl)methyl]-6- fluorospiro[isoquinoline-4(1H),3'-pyrrolidine]-1,2',3,5'(2H)-tetrone and congeners. 1. , 1994, Journal of medicinal chemistry.

[27]  M. Malamas,et al.  N-substituted spirosuccinimide, spiropyridazine, spiroazetidine, and acetic acid aldose reductase inhibitors derived from isoquinoline-1,3-diones. 2. , 1994, Journal of medicinal chemistry.

[28]  T. Matsui,et al.  Novel and potent aldose reductase inhibitors: 4-benzyl- and 4-(benzothiazol-2-ylmethyl)-3,4-dihydro-3-oxo-2H-1,4-benzothiazine-2-ac etic acid derivatives. , 1994, Chemical & pharmaceutical bulletin.

[29]  A. Del Corso,et al.  Thiol dependent oxidation of enzymes: the last chance against oxidative stress. , 1994, The International journal of biochemistry.

[30]  G. Camici,et al.  Glutathione dependent modification of bovine lens aldose reductase. , 1994, Experimental eye research.

[31]  G. Petsko,et al.  An anion binding site in human aldose reductase: mechanistic implications for the binding of citrate, cacodylate, and glucose 6-phosphate. , 1994, Biochemistry.

[32]  G. Petsko,et al.  Tyrosine-48 is the proton donor and histidine-110 directs substrate stereochemical selectivity in the reduction reaction of human aldose reductase: enzyme kinetics and crystal structure of the Y48H mutant enzyme. , 1994, Biochemistry.

[33]  B. Hulin.  New hypoglycaemic agents. , 1994, Progress in medicinal chemistry.

[34]  C. Lipinski,et al.  A perspective of aldose reductase inhibitors , 1993 .

[35]  F A Quiocho,et al.  Refined 1.8 A structure of human aldose reductase complexed with the potent inhibitor zopolrestat. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[36]  S. Genuth,et al.  The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. , 1993, The New England journal of medicine.

[37]  P. Oates,et al.  Aldose reductase inhibitors: recent developments. , 1993, Progress in drug research. Fortschritte der Arzneimittelforschung. Progres des recherches pharmaceutiques.

[38]  S. Srivastava,et al.  Does sorbinil bind to the substrate binding site of aldose reductase? , 1992, Biochemical pharmacology.

[39]  D. Borhani,et al.  The crystal structure of the aldose reductase.NADPH binary complex. , 1992, The Journal of biological chemistry.

[40]  M. Cotter,et al.  Dissociation between biochemical and functional effects of the aldose reductase inhibitor, ponalrestat, on peripheral nerve in diabetic rats , 1992, British journal of pharmacology.

[41]  C. Grimshaw.  Aldose reductase: model for a new paradigm of enzymic perfection in detoxification catalysts. , 1992, Biochemistry.

[42]  A. Bhatnagar,et al.  Aldose reductase: congenial and injurious profiles of an enigmatic enzyme. , 1992, Biochemical medicine and metabolic biology.

[43]  F A Quiocho,et al.  An unlikely sugar substrate site in the 1.65 A structure of the human aldose reductase holoenzyme implicated in diabetic complications. , 1992, Science.

[44]  C. Lipinski,et al.  Hydantoin bioisosteres. In vivo active spiro hydroxy acetic acid aldose reductase inhibitors. , 1992, Journal of medicinal chemistry.

[45]  B. Mylari,et al.  Orally active aldose reductase inhibitors: indazoleacetic, oxopyridazineacetic, and oxopyridopyridazineacetic acid derivatives. , 1992, Journal of medicinal chemistry.

[46]  M. Asao,et al.  Biological activities and quantitative structure-activity relationships of spiro[imidazolidine-4,4'(1'H)-quinazoline]-2,2',5(3'H)-triones as aldose reductase inhibitors. , 1992, Journal of medicinal chemistry.

[47]  T. Flynn,et al.  Studies on pig muscle aldose reductase. Kinetic mechanism and evidence for a slow conformational change upon coenzyme binding. , 1992, The Journal of biological chemistry.

[48]  B. Mylari,et al.  Potent, orally active aldose reductase inhibitors related to zopolrestat: surrogates for benzothiazole side chain. , 1992, Journal of medicinal chemistry.

[49]  D. Moras,et al.  Novel NADPH-binding domain revealed by the crystal structure of aldose reductase , 1992, Nature.

[50]  W. Ward,et al.  (2,6-Dimethylphenylsulphonyl)nitromethane: a new structural type of aldose reductase inhibitor which follows biphasic kinetics and uses an allosteric binding site. , 1991, Biochemical pharmacology.

[51]  J. Okuda,et al.  Properties of novel aldose reductase inhibitors, M16209 and M16287, in comparison with known inhibitors, ONO-2235 and sorbinil. , 1991, Chemical & pharmaceutical bulletin.

[52]  M. K. Sahib,et al.  Monoaminoguanidine inhibits aldose reductase. , 1991, Biochemical pharmacology.

[53]  C. Lipinski,et al.  pKa, Log P and MedChem CLOGP Fragment Values of Acidic Heterocyclic Potential Bioisosteres , 1991 .

[54]  B. Mylari,et al.  Novel, potent aldose reductase inhibitors: 3,4-dihydro-4-oxo-3-[[5-(trifluoromethyl)-2-benzothiazolyl] methyl]-1-phthalazineacetic acid (zopolrestat) and congeners. , 1991, Journal of medicinal chemistry.

[55]  C. Grimshaw,et al.  Mechanistic basis for nonlinear kinetics of aldehyde reduction catalyzed by aldose reductase. , 1990, Biochemistry.

[56]  O. Hayaishi,et al.  A superfamily of NADPH-dependent reductases in eukaryotes and prokaryotes. , 1989, Experimental eye research.

[57]  B. Wermuth,et al.  The aldo-keto reductase superfamily. cDNAs and deduced amino acid sequences of human aldehyde and aldose reductases. , 1989, The Journal of biological chemistry.

[58]  R. Sarges.  Aldose Reductase Inhibitors: Structure–Activity Relationships and Therapeutic Potential , 1989 .

[59]  S. Srivastava,et al.  Prevention of Sugar-Induced Cataractogenesis in Rats by Butylated Hydroxytoluene , 1988, Diabetes.

[60]  P. Kador.  The role of aldose reductase in the development of diabetic complications , 1988, Medicinal research reviews.

[61]  Christopher A. Lipinski,et al.  Medicinal chemistry of aldose reductase inhibitors , 1988, Medicinal research reviews.

[62]  R. Poulsom.  Comparison of aldose reductase inhibitors in vitro. Effects of enzyme purification and substrate type. , 1987, Biochemical pharmacology.

[63]  L. Humber.  The medicinal chemistry of aldose reductase inhibitors. , 1987, Progress in medicinal chemistry.

[64]  B. Griffin,et al.  Characterization of the reduction of 3-acetylpyridine adenine dinucleotide phosphate by benzyl alcohol catalyzed by aldose reductase. , 1986, Archives of biochemistry and biophysics.

[65]  N. Sharpless,et al.  Aldose reductase inhibitors: a potential new class of agents for the pharmacological control of certain diabetic complications. , 1985, Journal of medicinal chemistry.

[66]  J. A. Cromlish,et al.  Pig muscle aldehyde reductase. Identity of pig muscle aldehyde reductase with pig lens aldose reductase and with the low Km aldehyde reductase of pig brain and pig kidney. , 1983, The Journal of biological chemistry.

[67]  K. Inagaki,et al.  Affinity purification and glucose specificity of aldose reductase from bovine lens. , 1982, Archives of biochemistry and biophysics.